Press Releases

Featured
GOLDFINCH BIO INITIATES PHASE 1 CLINICAL TRIAL OF GFB-887 FOR KIDNEY DISEASE
Goldfinch Bio to Present at Upcoming Investor Conferences in June
GILEAD SCIENCES AND GOLDFINCH BIO ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NOVEL THERAPIES FOR KIDNEY DISEASE
Goldfinch Bio Presents Data Enabling the Advancement of Innovative Approaches to the Treatment of Kidney Disease at the International Society of Nephrology World Congress 2019
Goldfinch Bio to Present at the 2019 Needham & Company 18th Annual Healthcare Conference
Goldfinch Bio to Present at the Oppenheimer 29th Annual Healthcare Conference
Goldfinch Bio to Present at Cowen and Company 39TH Annual Health Care Conference
Frank S. Czerwiec, M.D., Ph.D. joins Goldfinch Bio as Chief Medical Officer
Goldfinch Bio Announces GFB-887 as Clinical Development Candidate and Presents Data Demonstrating Selective Inhibition of TRPC5 for the Treatment of Genetically-driven Kidney Disease
GOLDFINCH BIO TO PRESENT DATA ON TRPC5 INHIBITOR FOR PROTEINURIC KIDNEY DISEASE AND ITS KIDNEY GENOME ATLAS FOR IDENTIFICATION OF NOVEL TARGETS
Goldfinch Bio to Present at Jefferies 2018 Global Healthcare Conference
Goldfinch Bio Presents Data on TRPC5 Inhibition as a Target for Proteinuric Kidney Disease and Announces GFB-887 as Lead Drug Program to treat FSGS
Goldfinch Bio to Present at BioCentury’s Future Leaders in Biotech Industry Conference
Goldfinch Bio Bolsters Leadership Team by Appointing Dr. Peter Mundel as Chief Scientific Officer and Electing Dr. Frank Maddux to Board of Directors
Goldfinch Bio to Present at Cowen and Company Healthcare Conference
Goldfinch Bio Announces Collaborations with Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to Augment World’s Largest Genomic Registry of Patients with Kidney Disease
Goldfinch Bio and NEPTUNE Announce Collaboration to Discover New Treatments for Patients with Kidney Disease
Goldfinch Bio Expands Leadership Team with World-Class Preclinical and Clinical Expertise to Augment Company’s Unprecedented Investigation into the Molecular Drivers of Kidney Disease
Goldfinch Bio Appoints Nephrologist Louis Brenner, M.D., M.B.A. to Board of Directors
Third Rock Ventures launches Goldfinch Bio with $55M in Series A funding to bring precision medicine to patients with kidney disease